The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients
Neuro-Oncology Practice · 24.03.2023 · 10 (2) · 126-131
DOI: 10.1093/nop/npac070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 10.09.2022. Verfasst von Matthew Torre und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital and Harvard Medical School; Boston, MA, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
Background
Glioblastoma patients with hypermethylation of the O6-methylguanine-methyltransferase (MGMT) gene promoter have significantly improved survival when treated with temozolomide compared to patients with unmethylation of the MGMT promoter. However, the prognostic and predictive significance of partial MGMT promoter methylation is unclear.
Methods
The National Cancer Database was queried for patients newly diagnosed in 2018 with histopathologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma. The overall survival (OS) associated with MGMT promoter methylation status was assessed using multivariable Cox regression with Bonferroni correction for multiple testing (P < .008 was significant).
Results
Three thousand eight hundred twenty-five newly diagnosed IDH-wildtype glioblastoma patients were identified. The MGMT promoter was unmethylated in 58.7% (n = 2245), partially methylated in 4.8% (n = 183), hypermethylated in 3.5% (n = 133), and methylated not otherwise specified (NOS; likely consisting predominantly of hypermethylated cases) in 33.0% (n = 1264) of cases. Among patients that received first-line single-agent chemotherapy (ie likely temozolomide), compared to partial methylation (referent), MGMT promoter unmethylation was associated with worse OS (hazard ratio [HR] 1.94; 95% confidence interval [95 CI]: 1.54–2.44; P < .001) in multivariable Cox regression adjusted for major prognostic confounders. In contrast, a significant OS difference was not observed between partially methylated promoters and either hypermethylated (HR 1.02; 95 CI: 0.72–1.46; P = .90) or methylated NOS (HR 0.99; 95 CI: 0.78–1.26; P = .93) promoters. Among IDH-wildtype glioblastoma patients who did not receive first-line chemotherapy, MGMT promoter methylation status was not associated with significant differences in OS (P = 0.39–0.83).
Conclusions
Compared to MGMT promoter unmethylation, partial methylation was predictive of improved OS among IDH-wildtype glioblastoma patients treated with first-line single-agent chemotherapy—supporting the use of temozolomide therapy in these patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Brigham and Women's Hospital and Harvard Medical School; Boston, MA, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School; Boston, MA, USA.
- Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.
ORCID-Profile: J Bryan Iorgulescu
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Institutes of Health
- Conquer Cancer Foundation
- Sontag Foundation
Zitieren
APA
Torre, M., Wen, P. Y., & Iorgulescu, J. B. (2023). The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients. Neuro-Oncology Practice, 10(2), 126-131. https://doi.org/10.1093/nop/npac070
Vancouver
Torre M, Wen PY, Iorgulescu JB. The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients. Neuro-Oncology Practice. 2023;10(2):126-131. doi:10.1093/nop/npac070
BibTeX
@article{Torre2023,
author = {Torre, Matthew and Wen, Patrick Y and Iorgulescu, J Bryan},
title = {The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients},
journal = {Neuro-Oncology Practice},
year = {2023},
volume = {10},
number = {2},
pages = {126--131},
doi = {10.1093/nop/npac070}
}
EUVIMED